aap will discontinue parts of its standard trauma business at the end of FY/2019 within a cost reduction and efficiency enhancement program

The distribution of parts of the standard trauma portfolio is to be ceased at the end of financial year 2019. Sales of these products totalled around EUR 0.7 million in financial year 2018. The existing stocks of products of the standard trauma portfolio are to be sold off by the end of the current year. The decision was also taken against the background of the significantly increased regulatory requirements of the new EU Medical Device Regulation (MDR), which lead to considerable personnel and financial expenditures for aap. On the cost side, the discontinuation of parts of the standard trauma portfolio enables aap to avoid not only the expenditures of adapting processes and documents for these products to the increased regulatory requirements of MDR, but also the costs of maintaining their certification in accordance with the new Medical Device Regulation. The company concluded that it makes more economic sense to concentrate on the distribution of its innovative and higher-margin LOQTEQ(R) portfolio as well as its comprehensive range of cannulated screw products. In addition, the further development respectively market approval of the promising platform technologies silver coating and resorbable magnesium implants are to be pushed forward consequently.


 

---

----------------------------------------------------------------
aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany; Tel.: +49/30/750 19 - 134; Fax.: +49/30/750 19 - 290; f.franke@aap.de